By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity ...

Hello, and welcome to Wave Life Sciences Positive Interim Phase I Clinical Data from INLIGHT Trial of WVE-007 for Obesity Call. [Operator Instructions] Also, as a reminder, this conference is being ...

Wave Life Sciences has plummeted after two Wall Street firms cut price targets following updated trial data for the company's ...

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long ...

Anavex Life Sciences Corp. AVXL shares are tumbling on Wednesday after the company announced it has withdrawn its application ...

Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data ...

W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...

Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...

Dr. Mark Turco "will step down" from his role with the Hub Wednesday, March 11, to lead a medical device company.